Home › Trials › NCT06162221

Evaluating RAS inhibitors for advanced lung cancer

A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

PHASE1; PHASE2 · Revolution Medicines, Inc. · NCT06162221

This study is testing new RAS inhibitors combined with standard treatments to see if they can help people with advanced lung cancer that has specific RAS mutations.

Quick facts

PhasePHASE1; PHASE2
Study typeInterventional
Enrollment616 (estimated)
Ages18 Years and up
SexAll
SponsorRevolution Medicines, Inc. (industry)
Drugs / interventionspembrolizumab, chemotherapy
Locations89 sites (Gilbert, Arizona and 88 other locations)
Trial IDNCT06162221 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of novel RAS(ON) inhibitors in combination with standard cancer treatments for patients with advanced RAS-mutated non-small cell lung cancer (NSCLC). The study is structured as a platform trial with three subprotocols, each focusing on different combinations of RAS inhibitors and standard therapies. Patients with specific RAS mutations will be enrolled to determine the recommended doses and schedules for these treatments.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with advanced RAS-mutated NSCLC who have previously received standard therapy.

Not a fit: Patients with primary central nervous system tumors or significant gastrointestinal function impairment may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide new effective treatment options for patients with advanced RAS-mutated NSCLC.

How similar studies have performed: Other studies have shown promise with similar approaches targeting RAS mutations, indicating potential for success in this novel treatment strategy.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion criteria:

All Patients (unless otherwise noted):

* ≥ 18 years of age
* ECOG PS is 0 to 1
* Adequate organ function as outlined by the study
* Received prior standard therapy appropriate for tumor type and stage
* Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
* Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
* Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)

Exclusion criteria:

All Patients:

* Primary central nervous system (CNS) tumors
* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
* Major surgery \< 28 days of first dose
* Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids

Other inclusion/exclusion criteria may apply.

Where this trial is running

Gilbert, Arizona and 88 other locations

+39 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC, NSCLC, KRAS G12C, RAS Mutation

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.